Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs.

MLA

Kent, Seamus, et al. “Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs.” Circulation: Cardiovascular Quality & Outcomes, vol. 9, no. 4, July 2016, pp. 348–54. EBSCOhost, https://doi.org/10.1161/CIRCOUTCOMES.115.002592.

APA

Kent, S., Haynes, R., Hopewell, J. C., Parish, S., Gray, A., Landray, M. J., Collins, R., Armitage, J., Mihaylova, B., & HPS2-THRIVE Collaborative Group. (2016). Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs. Circulation: Cardiovascular Quality & Outcomes, 9(4), 348–354. https://doi.org/10.1161/CIRCOUTCOMES.115.002592

Chicago

Kent, Seamus, Richard Haynes, Jemma C. Hopewell, Sarah Parish, Alastair Gray, Martin J. Landray, Rory Collins, Jane Armitage, Borislava Mihaylova, and HPS2-THRIVE Collaborative Group. 2016. “Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs.” Circulation: Cardiovascular Quality & Outcomes 9 (4): 348–54. doi:10.1161/CIRCOUTCOMES.115.002592.